GlobeNewswire by notified

Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease

  • 1,374 patients enrolled into the phase 3 studyacross 369 global sites
  • Topline data anticipated in H1 2023
  • Galapagos will assumeresponsibility forthe DIVERSITY study

Mechelen, Belgium; 4 October 2021, 07.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced randomization of the last patient into the multi-center, globalDIVERSITY Phase 3 study. The study isdesigned to evaluate the efficacy and safety of filgotinib, a JAK1 preferential inhibitor, in the induction and maintenance of remission in patients with Crohn’s Disease (CD).

The DIVERSITY study enrolled 1,374 participants with moderately to severely active CD, including biologic-naïve and biologic-experienced patients. The study evaluates the safety and efficacy of 100mg and 200mg filgotinib versus placebo on clinical remission and endoscopic response, in a 10-week induction phase, followed by a 47-week maintenance phase. Topline results of the DIVERSITY study are anticipated in H1 2023.

Dr. Walid Abi-Saab, Chief Medical Officer, Galapagos NV said: “This is an important milestone in the DIVERSITY program, as it brings us closer to delivering robust evidence to assess the use of our JAK1 preferential inhibitor as a potentially new class of medicine in the treatment of patients with Crohn's Disease. I would like to thank the patients and the clinical trial centers for participating in this important program, especially during the recent COVID-19 pandemic, which has been a particularly challenging time for the health services and society as a whole.”

The DIVERSITY clinical program design was informed by results from the Phase 2 FITZROY study, with filgotinib, which provided positive results for the use of this JAK1 inhibitor in patients with active CD. Full results were reported in The Lancet.1

The use of filgotinib for CD is investigational and is not approved anywhere globally.

Galapagos will assume operational and financial responsibility for DIVERSITY
In agreement with Gilead, Galapagos will assume sponsorship of and operational and financial responsibility for the ongoing DIVERSITY clinical study, evaluating filgotinib in CD, and its long-term extension study. The parties intend to complete the transfer no later than June 30, 2022. Under the terms of the agreement and upon completion of the transfer, Gilead will make a one-time payment of $15 million to Galapagos in consideration for Galapagos assuming responsibility for the DIVERSITY clinical study. From April 1, 2022, Galapagos will also be solely responsible for all development costs for the DIVERSITY clinical study. In addition, if the European Medicines Agency grants regulatory approval of filgotinib for the treatment of CD based on data from the DIVERSITY trial, then royalties payable by Galapagos to Gilead will be reduced by 30% across all filgotinib indications and will become 5.6 to 10.5% of net sales in Europe. These royalties are payable as of 2024. Gilead remains responsible for commercial activities outside of Europe.

About Crohn’s Disease
Crohn’s disease is a type of inflammatory bowel disease in which the well-controlled balance of the intestinal immune system is disturbed. CD causes ulcerations that may affect any part of the digestive system from mouth to anus. The cause of the disease is unknown, with onset usually between the ages of 15 and 35. Patients suffer from abdominal pain, diarrhea (often blood), vomiting, fever and weight loss. Estimates suggest there could be up to 1.6 million people living with CD across Europe and up to 78,000 new cases every year.2

About the DIVERSITY Phase 3 Study
DIVERSITY consists of a combined, double-blind, placebo-controlled Phase 3 study, enrolling 1,374 patients from 369 centers worldwide. The study compares the efficacy of filgotinib 100mg or 200mg once-daily oral treatment versus placebo in the induction and maintenance of clinical remission measured by Crohn’s Disease Activity Index (CDAI) score and endoscopic response measured as simple endoscopic score for Crohn’s Disease (SES-CD) at week 10 and week 58, in biologically-naive and biologically-experienced patients with moderately to severely active CD. There are EU-specific co-primary objectives that evaluate clinical remission measured by Patient Reported Outcome (PR02) and endoscopic response (SES-CD) at Week-10 and Week-58. In addition to clinical endpoints the study will also evaluate the effects on Health-Related Quality of Life (HRQoL) scores and Health Care Resource Utilization (HCRU) at Week-10 and Week-58. Safety will be evaluated by assessment of clinical laboratory tests, physical examination, vital signs measurements at various timepoints during the study, and by the documentation of Adverse Events.

For DIVERSITY study information visit: Identifier NCT02048618

About the filgotinib collaboration
Gilead and Galapagos NV are partners in a global collaboration to develop and commercialize filgotinib, which is approved and marketed as Jyseleca® in the European Union, Great Britain, and Japan for the treatment of adults with moderate to severe active rheumatoid arthritis (RA) who have responded inadequately or are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs). Galapagos will be responsible for the commercialization of filgotinib in Europe (transition from Gilead to Galapagos anticipated to be completed by end of 2021), while Gilead will remain responsible for filgotinib outside of Europe, including in Japan, where filgotinib is co-marketed with Eisai. Applications to extend the approved indication of filgotinib to include ulcerative colitis have been filed in the European Union, Great Britain, and Japan, and a global Phase 3 program is ongoing in Crohn’s Disease. More information about clinical trials can be accessed at

The European Summary of Product Characteristics for filgotinib, which includes contraindications and special warnings and precautions, is available at The interview form from the Japanese Ministry of Health, Labour and Welfare is available at The individual Great Britain and Northern Ireland Summary of Product Characteristics can be found at and respectively.

Jyseleca® is a trademark of Galapagos NV and Gilead Sciences, Inc. or its related companies.

About Galapagos
Galapagos NV discovers, develops, and commercializes small molecule medicines with novel modes of action. Our pipeline comprises discovery through Phase 3 programs in inflammation, fibrosis, and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. More information at


Elizabeth Goodwin
VP Investor Relations
+1 781 460 1784

Sofie Van Gijsel
Senior Director Investor Relations
+1 781 296 1143

Sandra Cauwenberghs
Director Investor Relations
+32 495 58 46 63

Anna Gibbins
Senior Director Therapeutic Areas Communications
+44 7717 801900

Evelyn Fox
Director Executive Communications 
+31 65 3591 999

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements and, therefore, the reader should not place undue reliance on them. These risks, uncertainties and other factors include, without limitation, the inherent risks associated with clinical trial and product development activities, including the DIVERSITY study and filgotinib clinical program, the timeline of topline results from clinical trials, competitive developments, and regulatory approval requirements, including the risk that the results of the DIVERSITYstudy may not support continued approval of filgotinib or may not support registration or further development in CD or other indicationsdue to safety or efficacy concerns or other reasons, the timing or likelihood of regulatory authorities approval of marketing authorization for filgotinib for UC or any other indications, such regulatory authorities requiring additional studies, the risk that Galapagos will not be able to continue to execute on its currently contemplated business plan and/or will need to revise its business plan, the risk that the parties would not be able to complete the contemplated transfer of the DIVERSITY STUDY in a timely manner or at all, the risk that parties may not be able to successfully implement transfer of rights and activities in a timely or efficient manner or at all, Galapagos’ reliance on collaborations with third parties, including the collaboration with Gilead for filgotinib, the risk that Galapagos’ estimations regarding its filgotinib development program may be incorrect and the uncertainty regarding estimates of the commercial potential of filgotinib, the risks and costs involved in selling and marketing filgotinib, the timing of and risks related to the implementation of the transition of the European commercialization responsibility of filgotinib from Gilead to us, including the risk that the transition will not be completed on the currently contemplated timeline or at all, and the risk that the transition will not have the currently expected results for our business and results of operations; andthe uncertainties relating to the impact of the COVID-19 pandemic on our strategy, business plans and focus, as well as those risks and uncertainties identified in our Annual Report on Form 20-F for the year ended 31 December 2020 and our subsequent filings with the SEC. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The forward-looking statements contained herein are based on management’s current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no commitment to update or publicly release any revisions to forward-looking statements in order to reflect new information or subsequent events, circumstances or changes in expectations.

1The Lancet Vol. 389 No. 10066 p266–275 Published: December 14, 2016
2Journal of Crohn's and Colitis, Volume 7, Issue 4, May 2013, Pages 322 337,
3 (last accessed 01.09.21)


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Result of Riksbank´s purchases of Commercial Paper20.10.2021 10:00:00 CEST | Press release

AuctionAuction resultsAuction date2021-10-20Settlement date2021-10-22Credit rating class1Term3mFixed purchase rate, %0.3Total bid amount, SEK mln0Accepted volume, SEK mln0Percentage alloted, %0Number of bids0 AuctionAuction resultsAuction date2021-10-20Settlement date2021-10-22Credit rating class1Term6mFixed purchase rate, %0.4Total bid amount, SEK mln0Accepted volume, SEK mln0Percentage alloted, %0Number of bids0 AuctionAuction resultsAuction date2021-10-20Settlement date2021-10-22Credit rating class2Term3mFixed purchase rate, %0.6Total bid amount, SEK mln0Accepted volume, SEK mln0Percentage alloted, %0Number of bids0 AuctionAuction resultsAuction date2021-10-20Settlement date2021-10-22Credit rating class2Term6mFixed purchase rate, %0.7Total bid amount, SEK mln0Accepted volume, SEK mln0Percentage alloted, %0Number of bids0

Talenom Plc will publish its Business Review for January-September 2021 on Monday 1 November 2021 at 13:30 EET20.10.2021 09:45:00 CEST | Press release

Talenom Plc, Press release 20 October 2020 at 10:45 EEST Talenom Plc will publish its Business Review for January-September 2021 on Monday 1November 2021 at 13:30 EET Talenom Plc will publish its Business Review for January-September 2021 on Monday 1 November 2021 at 13:30 EET. The company’s CEO Otto-Pekka Huhtala will present the highlights of the Review for analysts, investors and media in Finnish, followed by CFO Antti Aho’s presentation in English as a live webcast that will be held on Monday 1 November 2021 at 14:00 EET. You can watch the webcast online at The presentation materials will be published before the start of the briefing on the company’s website at The briefing can also be followed at the company’s premises in Sanoma House (address: Töölönlahdenkatu 2, 00100 Helsinki). The registration is required at the latest on 27 October 2021, by email or by phone +358 207 525 403. TALENOM


Rovio Entertainment Corporation Press release ROVIO AND BILLEBEINO TEAM UP FOR A LIMITED-EDITION ANGRY BIRDS CAPSULE COLLECTION There's a new bird in town! The two Finnish companies, Rovio Entertainment and lifestyle brand Billebeino have collaborated on a new limited-edition Angry Birds capsule collection, in a deal brokered by IMG. The line features the iconic Angry Birds characters and a new exclusive character Bille Bird, based on Billebeino founder and former NHL player Ville Leino. The limited-edition garments land in select retailers and in the Billebeino online store today. The collection will include unisex casual wear and accessories for adults and children. The garments feature designs that combine the iconic Angry Birds characters with the minimalist and instantly recognizable logo and typeface styles that Billebeino has come to be known for. The aforementioned Bille Bird will appear in graphical placements that play on the fun and destructive nature of the Angry Birds, wit

PubMatic and Semasio Expand Partnership and Deliver Increased Reach for Omnicom Media Group20.10.2021 09:00:00 CEST | Press release

By activating Semasio’s audience segments within PubMatic’s Audience Encore, OMD Netherlands and OMG Germany engaged more consumers compared to DSP activation LONDON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Today, PubMatic, a sell-side platform that delivers superior outcomes for digital advertising, and Semasio, a pioneer in Unified Targeting which seamlessly combines audience and contextual targeting on the buy- and the sell-side, announced an expanded partnership that enables media buyers to increase audience addressability at a user- and page-level. Semasio’s audience and contextual segments can now be activated directly in PubMatic’s sell-side platform (SSP) for rapid, precision targeting. With the prevalence of third-party cookies continuing to decline and consumer privacy paramount, it is important for agencies to re-define audience addressability strategies to optimise reach. A common concern when targeting data segments is the risk of suboptimal reach due to poor cookie match rates.

Nexstim Plc Business and Clinical Update Q3 202120.10.2021 09:00:00 CEST | Press release

Press release,Helsinki, 20 October 2021 at10:00 AM (EEST) Nexstim Plc Business and Clinical Update Q3 2021 Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces the key highlights of the Company’s business and clinical progress during Q3 2021. CEO Mikko Karvinen’sBusiness and Clinical Update I’m very happy to inform that following the strongest first half in the history of the company, our operational business has continued to show positive progress during the third quarter of the year. We have continued to focus on the growth of our Diagnostics Business (NBS) and Therapy Business (NBT®) new system sales in both of our key markets in the United States and Europe. At the same time, we have seen interest in our existing NBS and NBT® System customer base for system upgrades and continued to increase the utilisation rate of our installed base to a record level. This has led into steadily growing recurring revenue levels, which creates stability and a new kind of predictabil

Nexstim Abp:s uppdatering om verksamheten och kliniska framstegen tredje kvartalet 202120.10.2021 09:00:00 CEST | Pressemelding

Pressmeddelande, Helsingfors, 20 oktober 2021 kl. 10.00(EEST) Nexstim Abp:s uppdatering om verksamheten och kliniska framstegen tredje kvartalet 2021 Nexstim Abp (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”bolaget”) redogör för de viktigaste händelserna i bolagets verksamhet och kliniska framsteg tredje kvartalet 2021. Vd Mikko Karvinens synpunkter på affärsverksamheten och kliniska framstegen Det gläder mig att kunna berätta att bolaget efter det starkaste halvåret i dess historia har haft fortsatt positiv tillväxt inom affärsverksamheten under tredje kvartalet. Vi har fortsatt att satsa på att öka försäljningen av nya system inom diagnostikverksamheten (NBS) och terapiverksamheten (NBT®) på bägge två av våra huvudmarknader, nämligen USA och Europa. Samtidigt har befintliga kunder för NBS och NBT® uppvisat ett intresse för systemuppgraderingar, vilket har bidragit till en rekordhög användningsfrekvens av den installerade basen. Som en följd har de återkommande intäkterna ökat, vilket ger

Yara reports improved returns20.10.2021 08:00:00 CEST | Press release

Oslo, 20 October 2021:Yara delivers improved returns reflectinghigher prices in third quarter.Net income was a negative USD 143 million, compared with a positive USD 340 million a year earlier. The negative net income includesa USD 355 million impairment ofSalitre assetsin line with Yara’sregulatory release dated1 August 2021,and a currency translation loss of USD 148 million. Excluding currency effects and special items, the basic earnings per share was USD 1.33 compared with USD 0.88 per share in third quarter 2020. The main elements of the third-quarter results are: Improved returns reflecting higher prices8.3% ROIC1, up from 7.9% a year earlier40% ammonia curtailment in Europe due to natural gas price spike “Yara delivers solid third quarter results, with EBITDA2 excluding special items up 37%, mainly thanks to improved margins. However, the gas price spike in Europe has led to Yara curtailing around 40% of its European ammonia production,” said Svein Tore Holsether, President and